In this study, we have used two TLR agonists known to have immune‐stimulatory properties: IMQ, a TLR7 ligand already approved for clinical use in dermatological cancers, and Poly(I:C), a TLR3 ligand, currently under investigation in early clinical trials as anti‐tumor vaccine adjuvant 28, 30, 33, 34, 35, 36. Here, TLR3 is linked to neoplasm.